Perspectives on lymphangiogenesis and angiogenesis in cancer
Identifieur interne : 005260 ( Main/Exploration ); précédent : 005259; suivant : 005261Perspectives on lymphangiogenesis and angiogenesis in cancer
Auteurs : Tanja Holopainen ; Maija Bry [Finlande] ; Kari Alitalo [Finlande] ; Anne Saaristo [Finlande]Source :
- Journal of Surgical Oncology [ 0022-4790 ] ; 2011-05-01.
Descripteurs français
- KwdFr :
- Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs), Facteur de croissance endothéliale vasculaire de type A (métabolisme), Humains, Inhibiteurs de l'angiogenèse (usage thérapeutique), Lymphangiogenèse, Néovascularisation pathologique (), Néovascularisation pathologique (physiopathologie), Thérapie moléculaire ciblée, Tumeurs (), Tumeurs (traitement médicamenteux).
- MESH :
- antagonistes et inhibiteurs : Facteur de croissance endothéliale vasculaire de type A.
- métabolisme : Facteur de croissance endothéliale vasculaire de type A.
- physiopathologie : Néovascularisation pathologique.
- traitement médicamenteux : Tumeurs.
- usage thérapeutique : Inhibiteurs de l'angiogenèse.
- Humains, Lymphangiogenèse, Néovascularisation pathologique, Thérapie moléculaire ciblée, Tumeurs.
English descriptors
- KwdEn :
- Angiogenesis Inhibitors (therapeutic use), Humans, Lymphangiogenesis, Molecular Targeted Therapy, Neoplasms (blood supply), Neoplasms (drug therapy), Neovascularization, Pathologic (physiopathology), Neovascularization, Pathologic (prevention & control), Vascular Endothelial Growth Factor A (antagonists & inhibitors), Vascular Endothelial Growth Factor A (metabolism).
- MESH :
- chemical , antagonists & inhibitors : Vascular Endothelial Growth Factor A.
- chemical , metabolism : Vascular Endothelial Growth Factor A.
- chemical , therapeutic use : Angiogenesis Inhibitors.
- blood supply : Neoplasms.
- drug therapy : Neoplasms.
- physiopathology : Neovascularization, Pathologic.
- prevention & control : Neovascularization, Pathologic.
- Humans, Lymphangiogenesis, Molecular Targeted Therapy.
Abstract
Tumor‐associated neovascularization allows tumor cells to express their critical growth advantage, whereas lymphatic invasion is crucial for the metastatic process. Various growth factors stimulate blood and lymphatic neovascularization and modulate vessel permeability in tumors. The first anti‐angiogenic drugs are already in routine use, and new anti‐vascular therapeutics are evaluated in clinical trials. Conversely, pro‐lymphangiogenic therapy could be implemented to treat cancer survivors suffering from secondary lymphedema. J. Surg. Oncol. 2011;103:484–488. © 2011 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jso.21808
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000097
- to stream Istex, to step Curation: 000097
- to stream Istex, to step Checkpoint: 000692
- to stream PubMed, to step Corpus: 002673
- to stream PubMed, to step Curation: 002673
- to stream PubMed, to step Checkpoint: 002673
- to stream Ncbi, to step Merge: 004263
- to stream Ncbi, to step Curation: 004263
- to stream Ncbi, to step Checkpoint: 004263
- to stream Main, to step Merge: 005299
- to stream Main, to step Curation: 005260
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Perspectives on lymphangiogenesis and angiogenesis in cancer</title><author><name sortKey="Holopainen, Tanja" sort="Holopainen, Tanja" uniqKey="Holopainen T" first="Tanja" last="Holopainen">Tanja Holopainen</name></author><author><name sortKey="Bry, Maija" sort="Bry, Maija" uniqKey="Bry M" first="Maija" last="Bry">Maija Bry</name></author><author><name sortKey="Alitalo, Kari" sort="Alitalo, Kari" uniqKey="Alitalo K" first="Kari" last="Alitalo">Kari Alitalo</name><affiliation><country>Finlande</country><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName><orgName type="university">Université d'Helsinki</orgName></affiliation></author><author><name sortKey="Saaristo, Anne" sort="Saaristo, Anne" uniqKey="Saaristo A" first="Anne" last="Saaristo">Anne Saaristo</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0202D30ADDCE46B69D29F62A76DFC87372CDE03C</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/jso.21808</idno><idno type="url">https://api.istex.fr/document/0202D30ADDCE46B69D29F62A76DFC87372CDE03C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000097</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000097</idno><idno type="wicri:Area/Istex/Curation">000097</idno><idno type="wicri:Area/Istex/Checkpoint">000692</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000692</idno><idno type="wicri:doubleKey">0022-4790:2011:Holopainen T:perspectives:on:lymphangiogenesis</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:21480240</idno><idno type="wicri:Area/PubMed/Corpus">002673</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002673</idno><idno type="wicri:Area/PubMed/Curation">002673</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002673</idno><idno type="wicri:Area/PubMed/Checkpoint">002673</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002673</idno><idno type="wicri:Area/Ncbi/Merge">004263</idno><idno type="wicri:Area/Ncbi/Curation">004263</idno><idno type="wicri:Area/Ncbi/Checkpoint">004263</idno><idno type="wicri:Area/Main/Merge">005299</idno><idno type="wicri:Area/Main/Curation">005260</idno><idno type="wicri:Area/Main/Exploration">005260</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Perspectives on lymphangiogenesis and angiogenesis in cancer<ref type="note" target="#fn1"></ref></title><author><name sortKey="Holopainen, Tanja" sort="Holopainen, Tanja" uniqKey="Holopainen T" first="Tanja" last="Holopainen">Tanja Holopainen</name></author><author><name sortKey="Bry, Maija" sort="Bry, Maija" uniqKey="Bry M" first="Maija" last="Bry">Maija Bry</name><affiliation wicri:level="1"><country xml:lang="fr">Finlande</country><wicri:regionArea>Molecular/Cancer Biology Laboratory, Research Program Unit, Department of Pathology, Haartman Institute, Institute for Molecular Medicine Finland, Helsinki University Central Hospital, Biomedicum Helsinki, University of Helsinki, Helsinki</wicri:regionArea><wicri:noRegion>Helsinki</wicri:noRegion></affiliation></author><author><name sortKey="Alitalo, Kari" sort="Alitalo, Kari" uniqKey="Alitalo K" first="Kari" last="Alitalo">Kari Alitalo</name><affiliation wicri:level="1"><country xml:lang="fr">Finlande</country><wicri:regionArea>Molecular/Cancer Biology Laboratory, Research Program Unit, Department of Pathology, Haartman Institute, Institute for Molecular Medicine Finland, Helsinki University Central Hospital, Biomedicum Helsinki, University of Helsinki, Helsinki</wicri:regionArea><wicri:noRegion>Helsinki</wicri:noRegion><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName><orgName type="university">Université d'Helsinki</orgName></affiliation></author><author><name sortKey="Saaristo, Anne" sort="Saaristo, Anne" uniqKey="Saaristo A" first="Anne" last="Saaristo">Anne Saaristo</name><affiliation wicri:level="1"><country xml:lang="fr">Finlande</country><wicri:regionArea>Molecular/Cancer Biology Laboratory, Research Program Unit, Department of Pathology, Haartman Institute, Institute for Molecular Medicine Finland, Helsinki University Central Hospital, Biomedicum Helsinki, University of Helsinki, Helsinki</wicri:regionArea><wicri:noRegion>Helsinki</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Finlande</country><wicri:regionArea>Plastic Surgery, Turku University Central Hospital</wicri:regionArea><wicri:noRegion>Turku University Central Hospital</wicri:noRegion></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Surgical Oncology</title><title level="j" type="sub">The Pivotal Role of the Lymphovascular System in Cancer Metastasis</title><title level="j" type="alt">JOURNAL OF SURGICAL ONCOLOGY</title><idno type="ISSN">0022-4790</idno><idno type="eISSN">1096-9098</idno><imprint><biblScope unit="vol">103</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="484">484</biblScope><biblScope unit="page" to="488">488</biblScope><biblScope unit="page-count">5</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-05-01">2011-05-01</date></imprint><idno type="ISSN">0022-4790</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-4790</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiogenesis Inhibitors (therapeutic use)</term><term>Humans</term><term>Lymphangiogenesis</term><term>Molecular Targeted Therapy</term><term>Neoplasms (blood supply)</term><term>Neoplasms (drug therapy)</term><term>Neovascularization, Pathologic (physiopathology)</term><term>Neovascularization, Pathologic (prevention & control)</term><term>Vascular Endothelial Growth Factor A (antagonists & inhibitors)</term><term>Vascular Endothelial Growth Factor A (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs)</term><term>Facteur de croissance endothéliale vasculaire de type A (métabolisme)</term><term>Humains</term><term>Inhibiteurs de l'angiogenèse (usage thérapeutique)</term><term>Lymphangiogenèse</term><term>Néovascularisation pathologique ()</term><term>Néovascularisation pathologique (physiopathologie)</term><term>Thérapie moléculaire ciblée</term><term>Tumeurs ()</term><term>Tumeurs (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Vascular Endothelial Growth Factor A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Vascular Endothelial Growth Factor A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type A</term></keywords><keywords scheme="MESH" qualifier="blood supply" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type A</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Néovascularisation pathologique</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Neovascularization, Pathologic</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Neovascularization, Pathologic</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de l'angiogenèse</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Lymphangiogenesis</term><term>Molecular Targeted Therapy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Lymphangiogenèse</term><term>Néovascularisation pathologique</term><term>Thérapie moléculaire ciblée</term><term>Tumeurs</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tumor‐associated neovascularization allows tumor cells to express their critical growth advantage, whereas lymphatic invasion is crucial for the metastatic process. Various growth factors stimulate blood and lymphatic neovascularization and modulate vessel permeability in tumors. The first anti‐angiogenic drugs are already in routine use, and new anti‐vascular therapeutics are evaluated in clinical trials. Conversely, pro‐lymphangiogenic therapy could be implemented to treat cancer survivors suffering from secondary lymphedema. J. Surg. Oncol. 2011;103:484–488. © 2011 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Finlande</li></country><region><li>Uusimaa</li></region><settlement><li>Helsinki</li></settlement><orgName><li>Université d'Helsinki</li></orgName></list><tree><noCountry><name sortKey="Holopainen, Tanja" sort="Holopainen, Tanja" uniqKey="Holopainen T" first="Tanja" last="Holopainen">Tanja Holopainen</name></noCountry><country name="Finlande"><noRegion><name sortKey="Bry, Maija" sort="Bry, Maija" uniqKey="Bry M" first="Maija" last="Bry">Maija Bry</name></noRegion><name sortKey="Alitalo, Kari" sort="Alitalo, Kari" uniqKey="Alitalo K" first="Kari" last="Alitalo">Kari Alitalo</name><name sortKey="Saaristo, Anne" sort="Saaristo, Anne" uniqKey="Saaristo A" first="Anne" last="Saaristo">Anne Saaristo</name><name sortKey="Saaristo, Anne" sort="Saaristo, Anne" uniqKey="Saaristo A" first="Anne" last="Saaristo">Anne Saaristo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005260 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005260 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0202D30ADDCE46B69D29F62A76DFC87372CDE03C
|texte= Perspectives on lymphangiogenesis and angiogenesis in cancer
}}
| This area was generated with Dilib version V0.6.31. |  |